Last reviewed · How we verify
NCT06746714
Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
NA trial testing Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia) in Diabetes in 200 participants. Completed in 20 December 2024.
22 July 2024
Quick facts
| Lead sponsor | Kaiser Permanente |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 200 |
| Start date | 20 July 2023 |
| Primary completion | 22 July 2024 |
| Estimated completion | 20 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)
- Usual care, after system-side dissemination of HOAP
Conditions studied
- Diabetes — all drugs for Diabetes →
Sponsor
Kaiser Permanente — full company profile →
Who can join
18 and older, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Severe low blood sugar (hypoglycemia) is a serious problem for people with diabetes. It can lead to dangerous falls, heart problems, memory issues, and even death. However, many healthcare providers don't recognize or manage this problem well. The investigators believe that creating a clear set of guidelines for preventing hypoglycemia, along with having a clinical pharmacist actively help high-risk patients, can make diabetes treatment safer. In this study, the investigators developed a simple, evidence-based guide called "Hypoglycemia on a Page" (HOAP) to prevent low blood sugars. The investigators then tested it by comparing two groups of patients with type 2 diabetes who are at high risk for hypoglycemia. One group received active support from a clinical pharmacist using the HOAP guidelines, while the other group received standard care. The main goal of this study is to see if the pharmacist's support leads to safer diabetes treatment. The investigators will also look at other factors, such as whether patients are prescribed glucagon (a medicine for severe low blood sugar), if they use continuous glucose monitoring, and whether they have worse blood sugar control or end up in the hospital for hypoglycemia. This trial aims to improve patient safety, health outcomes, and possibly lower healthcare costs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk: A Randomized Clinical Trial.
Gilliam LK, Parker MM, Chen MW, Karter AJ, et al · · 2026 · PMID 41706448 · DOI 10.1001/jamanetworkopen.2025.59946
Verify or expand the search:
- PubMed search for NCT06746714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Kaiser Permanente trials
Trials by the same sponsor.
- NCT07522645 — Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Dis · NA · not yet recruiting
- NCT07474038 — AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment · NA · enrolling by invitation
- NCT07467668 — Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure · NA · not yet recruiting
- NCT07216859 — Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI) · NA · not yet recruiting
- NCT07264062 — MetSense Pilot and Feasibility · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06746714 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaiser Permanente
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06746714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing